linjc16/ctgov huggingface dataset:
Effects of Sage on Memory and Mental Performance in Alzheimer's Disease Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effectiveness of the herb sage in improving the mental function of individuals with Alzheimer's disease. Study hypothesis: The administration of sage will improve cognitive function in patients with mild Alzheimer's disease.

Detailed Description
-----------------
The herb sage has been shown to enhance memory and mental function in healthy, young adults. However, studies assessing the herb's effectiveness in older adults with symptoms of Alzheimer's disease are limited. This study will determine the effect of sage extract on the cognitive function of patients with mild Alzheimer's disease. This study will last 6 weeks and will comprise 4 study visits, approximately 10 days apart. Participants will be randomly assigned to receive either sage pills or no treatment during each 10-day period. The treatment assignments will be switched in 10-day intervals, so that during the course of the study, each participant will undergo two periods of sage treatment and two periods without treatment. At each study visit, participants will undergo cognitive testing, including tests to determine attention, memory, and visual cognition. Participants will also undergo an electroencephalogram (EEG) and an electrocardiogram (ECG) at each visit.

Official Title
-----------------
Effects of a Cognitive Enhancer on Memory and Cognitive Performance

Conditions
-----------------
Alzheimer Disease

Intervention / Treatment
-----------------
* Drug: Salvia officinalis (sage)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of mild Alzheimer's disease Partner, friend, child, spouse, or relative willing to accompany participants to all study visits, provide informed consent, monitor participants' pill-taking, and communicate changes in participants' health during the study Exclusion Criteria: Significant medical illness other than Alzheimer's disease

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Sage capsules taken by mouth | Drug: Salvia officinalis (sage)<br>* oral dosage<br>* Other names: sage;|
| No Intervention: 2<br>No intervention, no-pill as control | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cognitive function |  | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stress |  | 8 weeks | 
| cognitive electrophysiology |  | 8 weeks |
Semaglutide vs Dulaglutide on Epicardial Adipose Tissue

Study Overview
=================
Brief Summary
-----------------
Epicardial Fat (EAT), the visceral fat depot of the heart, is a modifiable cardio-metabolic risk factor and therapeutic target. EAT expresses GLP-1 receptors (GLP-1R). GLP-1 receptor agonist liraglutide is known to significantly decrease EAT thickness. However, the effects of GLP-1 receptor agonists semaglutide and dulaglutide on EAT thickness are unknown

Detailed Description
-----------------
This is a retrospective, observational, case control study. Data were obtained from retrospective review of the electronic medical records. Patients were treated with either semaglutide, dulaglutide or metformin as standard of care, during routine clinical practice, regardless of the study. Each patient underwent routine labs and an onsite ultrasound measurement of EAT thickness at baseline and at the routine 12-week follow up visit, as standard of care.

Official Title
-----------------
Effects of Semaglutide vs Dulaglutide on Epicardial Adipose Tissue Thickness in Subjects With Type 2 Diabetes and Obesity

Conditions
-----------------
Epicardial Fat

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetes, BMI ≥27 kg/m2, Age ≥ 18 years old Exclusion Criteria: Type 1 diabetes Concurrent use of dipeptidyl peptidase 4 (DPP-4) inhibitors or other GLP-1 agonist receptors History of diabetic ketoacidosis Known contraindications to GLP-1 receptor agonists such as previous history of pancreatitis or medullary thyroid carcinoma, personal or family history of multiple endocrine neoplasia type 2 Acute infective diseases, cancer or chemotherapy Use of systemic corticosteroids within the 3 months prior this study Known or suspected allergy to semaglutide or dulaglutide excipients or related products Pregnancy, breastfeeding or the intention of becoming pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Semaglutide<br>Patients using standard of care weekly GLP-1A analog Semaglutide | |
| Dulaglutide<br>Patients using standard of care weekly GLP-1A analog Dulaglutide | |
| Metformin<br>Patients using standard of care daily Metformin. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Epicardial Fat thickness | Ultrasound measured Epicardial Fat thickness | 12 weeks |
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension

Conditions
-----------------
Open-angle Glaucoma, Ocular Hypertension

Intervention / Treatment
-----------------
* Drug: Travoprost, Investigational
* Drug: Travoprost (TRAVATAN)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients of either sex of any race diagnosed with open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component) or ocular hypertension. Other protocol-defined inclusion criteria may apply. Exclusion Criteria: Under age 18. Other protocol-defined exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Travatan, Investigational<br> | Drug: Travoprost, Investigational<br>* One drop in study eye once daily for 13 days<br>|
| Active Comparator: Travatan<br> | Drug: Travoprost (TRAVATAN)<br>* One drop in study eye once daily for 13 days<br>* Other names: TRAVATAN;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean IOP |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
open-angle, glaucoma, ocular, hypertension
Developmental Dyslexia and Functional Maturation of Auditory Cortex

Study Overview
=================
Brief Summary
-----------------
Developmental dyslexia is a frequent learning disability. The aim of this study is to compare auditory evoked cortical responses to syllables and tones in developmental dyslexia and controls (paired with age, gender). The study is conducted in 3 groups of subjects :8-10 years ; 11-17 years and 18-25 years. We suppose that cortical responses should be different in developmental dyslexia and controls.

Conditions
-----------------
Developmental Reading Disorder, Dyslexia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age (8-10 years ; 11-17 years ; 18-25 years developmental reading disorders (developmental dyslexia) criteria according to Critchley (1970) PIQ > 85 No auditory deficit No psychosis - Exclusion Criteria: PIQ < 85 Epilepsy ADHD Stroke, head injury -

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adult dyslexia<br>Adult dyslexia | |
| Minor-Dyslexia<br>Minor-Dyslexia | |
| Adult-Control<br>Adult-Control | |
| Minor-Control<br>Minor-Control | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Use of Platelet Rich Plasma (PRP) for Improving Thin Endometrium

Study Overview
=================
Brief Summary
-----------------
Platelets rich plasma is simple source of growth factors and cytokines that can regulate endometrial growth for subgroup of thin endometrium women. It is an autologous source of this enhancing factors; therefore, there os no risk of using it within the same participant.

Official Title
-----------------
Use of Platelet Rich Plasma (PRP) for Improving Thin Endometrium For IVF Women

Conditions
-----------------
Poor Endometrium

Intervention / Treatment
-----------------
* Other: Treatment of Thin Endometrium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women with thin endometrium Exclusion Criteria: serum positive hepatitis B and C women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PRP injection into Uterine Cavity<br>PRP injection into Uterine Cavity For Treatment of Thin Endometrium | Other: Treatment of Thin Endometrium<br>* This is a trial to improve endometrial thickness by autologous injection of PRP into the Uterine Cavity compared with CSF or no treatment.<br>|
| Experimental: CSF (colony stimulating factor)<br>CSF for Treatment of Thin Endometrium | Other: Treatment of Thin Endometrium<br>* This is a trial to improve endometrial thickness by autologous injection of PRP into the Uterine Cavity compared with CSF or no treatment.<br>|
| No Intervention: No intervention<br>The control arm. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean Diameter of endometrial thickness | How the endometrium would respond after 2 days of PRP | 2 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical pregnancy rate | Registered fetal heartbeat 4 weeks or beyond after embryo transfer. | 4 weeks or beyond after embryo Transfer |
Spirometry in Esophageal Intubation

Study Overview
=================
Brief Summary
-----------------
The primary objective of the study is to describe the pressure patterns during esophageal and tracheal ventilation and to validate the diagnostic algorithm.

Official Title
-----------------
Analysis of the Spirometry Pattern in Esophageal Intubation

Conditions
-----------------
Esophageal Intubation

Intervention / Treatment
-----------------
* Other: tracheal ventilation with regular tube
* Other: ventilation after intubation with special tube


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients, requiring total anesthesia for a surgical procedure where the use of the easytube could be indicated. Exclusion Criteria: ASA III Expected difficulty for oral intubation. Expected operation time >3 hours

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 10 Asa I & II patients<br> | Other: tracheal ventilation with regular tube<br>* Description of the pressure waveforms during tracheal ventilation<br>Other: ventilation after intubation with special tube<br>* Description of the pressure waveforms during esophageal ventilation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determination of the sensitivity and specificity of the algorithm to detect esophageal intubation. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pressure pattern of ventilation in esophageal and tracheal ventilation. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pressure pattern, esophageal and tracheal ventilation., esophageal intubation.
A Study of Fortigel Testosterone Gel 2% in Males With Low Testosterone

Study Overview
=================
Brief Summary
-----------------
Low testosterone is a condition that occurs when the body is unable to produce sufficient quantities of testosterone. The medical name for low testosterone is hypogonadism. Hypogonadism can be caused by many factors. Symptoms include: decrease in libido, lack of energy and mood swings. The goal of testosterone replacement therapy is to return testosterone levels to the normal range and relieve symptoms. The purpose of this study is to evaluate the ability of Fortigel testosterone gel 2% to maintain serum (blood) testosterone levels within the normal range in hypogonadal men aged 18 to 75 years. This will be determined by blood sampling at specified times during the study. The study is also intended to evaluate the tolerability of Fortigel, which will be applied to the skin each day throughout the study period.

Official Title
-----------------
An Open Label Phase 3 Study of Fortigel Testosterone Gel 2% in Hypogonadal Males

Conditions
-----------------
Hypogonadism

Intervention / Treatment
-----------------
* Drug: Testosterone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men aged 18 - 75 years with primary or secondary hypogonadism as confirmed by: Single serum total testosterone concentration < 250 ng/dL, or Two consecutive serum total testosterone concentrations < 300 ng/dL (determined at least one week apart during the screening period). Has a BMI ≥ 22 kg/m2 and < 35 kg/m2.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>2% testosterone gel | Drug: Testosterone<br>* 2% gel<br>* Other names: Fortigel;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Participants Meeting Serum Total Testosterone Average Concentration (Cavg) Criteria at Day 90 | Percentage of participants with Cavg0-24h ≥300-≤1140 ng/dL | 0, 0.5, 1, 2, 4, 6, 8, 10, 12 and 24 hours after study drug application on day 90 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Participants Meeting Serum Total Testosterone Maximum Concentration (Cmax) Criteria at Day 90 | Percentage of participants with Cmax ≤1500 ng/dL, 1800-2500 ng/dL, and >2500 ng/dL | 0, 0.5, 1, 2, 4, 6, 8, 10, 12 and 24 hours after study drug application on day 90 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypogonadism
The Use of Pedometers as an Adjunctive Tool in a School-based Pediatric Weight Management Program

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is: To validate the use of pedometers in assessing the level of physical activity in middle school children. To evaluate whether setting a step goal through the use of pedometers could increase physical activity and prevent weight gain in middle school children.

Official Title
-----------------
The Use of Pedometers as an Adjunctive Tool in a School-based Pediatric Weight Management Program

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Behavioral: Goal-setting group
* Behavioral: Control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All healthy 8th grade students at the Springboard Academy of the Milton Hershey School willing to participate in the study and whose parents give consent. Exclusion Criteria: Any medical condition that prevents the child from walking during the 12 week study period. Non-English speaking student.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Control<br>The control group will be advised to continue to be physically active and record daily steps | Behavioral: Control<br>* The control group will be advised to continue to be physically active and record daily steps<br>|
| Active Comparator: Goal-setting group<br>This intervention group would be instructed to increase their daily step count by at least 20% above their baseline gradually over 3 months. | Behavioral: Goal-setting group<br>* This intervention group will be advised to increase their daily steps by at least 20% gradually over 3 months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body mass index | BMI will be recorded | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Daily step counts | Daily step count will be recorded | 3 months | 
| Survey questionnaire | Participants will be asked to fill out a survey | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obesity, Physical activity, pedometers, children
Institut Paoli-Calmettes Pancreatic Neoplasms Database

Study Overview
=================
Brief Summary
-----------------
Database of Institut Paoli Calmettes diagnosed with Pancreatic neoplasms

Official Title
-----------------
Institut Paoli-Calmettes Pancreatic Neoplasms Database

Conditions
-----------------
Pancreatic Neoplasms

Intervention / Treatment
-----------------
* Other: Data collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with a diagnosis of Pancreatic neoplasm Exclusion Criteria: Patient with a diagnosis of cholangiocarcinoma

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with diagnosis of Pancreatic neoplasms<br> | Other: Data collection<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival of patients with pancreatic neoplasms | Overall survival of all patients who come in the center | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collection of patients characteristics | Collection of characteristics of patients treated at Institut Paoli Calmettes in order to set up prospective and retrospective studies | 10 years |
4% Intrauterine Lidocaine Infusion for Pain Management in First Trimester Abortions

Study Overview
=================
Brief Summary
-----------------
Recent studies have investigated the use of local anesthetics (i.e. lidocaine, mepivacaine) to lessen the pain experienced with minor gynecologic procedures such as endometrial biopsy and office hysteroscopy. Local anesthetic injected into the uterine cavity has been demonstrated effective in some studies at decreasing patient pain associated with these intrauterine procedures at an anesthetic concentration of at least 2%. Based on this evidence, we hypothesized that an intrauterine lidocaine infusion may reduce patient pain during first trimester abortions.

Official Title
-----------------
4% Intrauterine Lidocaine Infusion for Pain Management in First Trimester Abortions

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Drug: Intrauterine lidocaine infusion 4%


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years old Good general health English speaking Confirmation of gestational age by ultrasound Body weight > 100 lbs. Pregnancy < 11 weeks

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Intrauterine lidocaine infusion 4%|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VAS scores during cervical dilation and uterine aspiration |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient satisfaction, symptoms, lidocaine levels |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pain with procedures